Literature DB >> 29172089

Retargeted and detargeted adenovirus for gene delivery to the muscle.

Tien V Nguyen1, Stephanie S Anguiano-Zarate2, William E Matchett3, Mary E Barry1, Michael A Barry4.   

Abstract

We previously selected muscle binding peptides 12.51 and 12.52 from "context-specific" phage display libraries for introduction into adenovirus (Ad) vectors. In this work, these peptides were inserted into the hypervariable region (HVR) 5 loop of the Ad5 hexon protein to display 720 peptides per virions. HVR-12.51 and 12.52 increased transduction of C2C12 cells up to 20-fold when compared to unmodified Ad5. 12.51 increased in vivo muscle transduction 2 to 7-fold over unmodified Ad after intramuscular injection in mice and hamsters. 12.52 did not increase muscle transduction. Notably, insertion of 12.51 into the hexon reduced liver transduction 80-fold when compared to unmodified Ad5 after intravenous injection. Increased muscle transduction in mice translated into increased immune responses after gene-based vaccination. These data suggest there are merits to retargeting and detargeting benefits to modifying the hexons of Ads with peptide ligands.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenovirus; Detargeting; Hexon; Hypervariable region; Phage peptide libraries; Targeting

Mesh:

Substances:

Year:  2017        PMID: 29172089      PMCID: PMC8819666          DOI: 10.1016/j.virol.2017.10.005

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  45 in total

1.  Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer.

Authors:  Reeti Khare; Shannon M May; Francesco Vetrini; Eric A Weaver; Donna Palmer; Amanda Rosewell; Nathan Grove; Philip Ng; Michael A Barry
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

2.  Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening.

Authors:  Ping Wu; Tarana A Kudrolli; Wasim H Chowdhury; Minzhi M Liu; Ronald Rodriguez; Shawn E Lupold
Journal:  Cancer Res       Date:  2010-07-29       Impact factor: 12.701

3.  Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment.

Authors:  T J Wickham; P Mathias; D A Cheresh; G R Nemerow
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

4.  Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors.

Authors:  Reeti Khare; Vijay S Reddy; Glen R Nemerow; Michael A Barry
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

5.  Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors.

Authors:  Qi Qiu; Zhili Xu; Jie Tian; Rituparna Moitra; Sreenivasulu Gunti; Abner L Notkins; Andrew P Byrnes
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

6.  Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.

Authors:  Zhili Xu; Qi Qiu; Jie Tian; Jeffrey S Smith; Gina M Conenello; Takashi Morita; Andrew P Byrnes
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

7.  IIIa deleted adenovirus as a single-cycle genome replicating vector.

Authors:  Catherine M Crosby; Michael A Barry
Journal:  Virology       Date:  2014-07-02       Impact factor: 3.616

8.  Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.

Authors:  O Kalyuzhniy; N C Di Paolo; M Silvestry; S E Hofherr; M A Barry; P L Stewart; D M Shayakhmetov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

9.  A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity.

Authors:  G Acsadi; A Jani; B Massie; M Simoneau; P Holland; K Blaschuk; G Karpati
Journal:  Hum Mol Genet       Date:  1994-04       Impact factor: 6.150

10.  Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification.

Authors:  M Brandon Parrott; Kristen E Adams; George T Mercier; Hoyin Mok; Samuel K Campos; Michael A Barry
Journal:  Mol Ther       Date:  2003-10       Impact factor: 11.454

View more
  4 in total

1.  Breaking tolerance with engineered class I antigen-presenting molecules.

Authors:  Christopher A Parks; Kalli R Henning; Kevin D Pavelko; Michael J Hansen; Virginia P Van Keulen; Brendan K Reed; Jennifer D Stone; Adam G Schrum; Diana Gil; David M Kranz; Andrew J Bordner; Michael A Barry; Larry R Pease
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-06       Impact factor: 11.205

Review 2.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

Review 3.  Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies.

Authors:  Tabitha G Cunliffe; Emily A Bates; Alan L Parker
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

Review 4.  Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses.

Authors:  Lucas J Kerstetter; Stephen Buckley; Carly M Bliss; Lynda Coughlan
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.